[1] |
Wechalekar AD, Cibeira MT, Gibbs SD, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group [J]. Amyloid, 2023, 30(1):3-17.
|
[2] |
Masood A, Ehsan H, Iqbal Q, et al. Treatment of light chain deposition disease: a systematic review [J]. J Hematol, 2022,11(4):123-130.
|
[3] |
Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group [J]. Nat Rev Nephrol,2019,15(1):45-59.
|
[4] |
Wang Q, Jiang F, Xu G. The pathogenesis of renal injury and treatment in light chain deposition disease [J]. J Transl Med,2019,17(1):387.
|
[5] |
Said SM, Best Rocha A,Valeri AM,et al. The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis [J]. Kidney Int, 2022, 101(1): 152-163.
|
[6] |
Darouich S, Bettaieb I, Aouadia R, et al. Light chain nephropathy [J]. Saudi J Kidney Dis Transpl, 2015, 26(3):437-442.
|
[7] |
Abildgaard N, Rojek AM, Møller HE, et al. Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits [J]. Amyloid,2020,27(1):59-66.
|
[8] |
李航, 李超. 具有肾脏意义的单克隆免疫球蛋白病的诊断体会[J]. 肾脏病与透析肾移植杂志,2024,33(1):45-46.
|
[9] |
Yadav P, Leung N, Sanders PW, et al. The use of immunoglobulin light chain assays in the diagnosis of paraproteinrelated kidney disease [J]. Kidney Int,2015,87(4):692-697.
|
[10] |
Cohen C, Joly F, Sibille A, et al. Randall-type monoclonal immunoglobulin deposition disease: new insights into the pathogenesis, diagnosis and management [ J]. Diagnostics(Basel, Switzerland),2021,11(3):420.
|
[11] |
Joly F, Cohen C, Javaugue V, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study [J]. Blood,2019,133(6):576-587.
|
[12] |
邵小磊, 洪权, 刘娇娜, 等. 具有肾脏意义的单克隆免疫球蛋白病合并低尿酸血症1 例[J/CD]. 中华肾病研究电子杂志,2023,12(2):115-116.
|
[13] |
Petrakis I, Stylianou K, Mavroeidi V, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation [J]. Nephrol Dial Transplant, 2010,25(6):2020-2023.
|
[14] |
Abdallah AA, Alapat D, Kaur V, et al. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease [J]. J Oncol Pharm Pract, 2020, 26(5):1128-1133.
|
[15] |
Rendo M, Franks TJ, Galvin JR, et al. Autologous stem cell transplantation in the treatment of pulmonary light chain deposition disease [J]. Chest,2021,160(1): e13-e17.
|
[16] |
González-López TJ, Vázquez L, Flores T, et al. Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation [J]. Clin Pract,2011,1(4): e95.
|
[17] |
Adamu B, Al-Ghamdi M, Ahmad M, et al. Treatment of light chain deposition disease using bortezomib-based regimen followed by thalidomide-based regimen in a Saudi male [J]. Case Rep Nephrol,2016,2016:7485695.
|
[18] |
Dutta A,Kesari K,Singh T. Cyclophosphamide,bortezomib and dexamethasone (CyBorD): a promising regimen for renal light chain deposit disease [J]. BMJ Case Rep, 2020, 13(1):e232985.
|
[19] |
Milani P, Basset M, Curci P, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function [J]. Blood Adv,2020,4(7): 1321-1324.
|
[20] |
Tsushima T, Suzuki T, Terao T, et al. Light chain deposition disease involving kidney and liver in a patient with IgD myeloma[J]. BMC Nephrol,2021,22(1):40.
|
[21] |
Kastritis E, Rousakis P, Kostopoulos IV, et al. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease [J]. Amyloid,2021,28(4):259-266.
|
[22] |
Blair HA. Daratumumab: a review in newly diagnosed systemic light chain amyloidosis [J]. Drugs,2022,82(6):683-690.
|
[23] |
Leypoldt LB, Gavriatopoulou M, Besemer B, et al.Daratumumab, bortezomib, and dexamethasone for treatment of patients with relapsed or refractory multiple myeloma and severe renal impairment: results from the phase 2 GMMG-DANTE trial[J]. Cancers (Basel),2023,15(18):4667.
|
[24] |
Kuzume A, Tabata R, Terao T, et al. Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure [J]. Br J Haematol,2021,193(4): e33-e36.
|
[25] |
Kastritis E, Palladini G, Minnema MC, et al. Daratumumabbased treatment for immunoglobulin light-chain amyloidosis [J].N Engl J Med,2021,385(1):46-58.
|
[26] |
Michaleas S, Penninga E, Hovgaard D, et al. EMA review of daratumumab (Darzalex) for the treatment of adult patients newly diagnosed with multiple myeloma [J]. Oncologist, 2020, 25(12):1067-1074.
|
[27] |
Nahi H,Chrobok M,Gran C,et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma [J]. PLoS One,2019,14(2): e0211927.
|
[28] |
Hill E, Morrison C, Kazandjian D. Daratumumab: a review of current indications and future directions [J]. Semin Oncol,2022,49(1):48-59.
|
[29] |
Xu XS, Dimopoulos MA, Sonneveld P, et al. Pharmacokinetics and exposure-response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma [J]. Adv Ther,2018,35(11):1859-1872.
|
[30] |
Clemens PL, Yan X, Lokhorst HM, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment [J]. Clin Pharmacokinet,2017,56(8):915-924.
|